| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:16513093 | IVTH | 0.000000001 - 0.00001 M | 0.0000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:17644232 | IVR | 2 mg/kg | - | No significant effects observed | - |
| IVR | 6 mg/kg | 6 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Undescended testes (or cryptorchidism) | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:19464569 | IVR | 2 mg/kg | 2 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg | 2 mg/kg | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 6 mg/kg | - | No significant effects observed | - | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Alterations in preputial separation | Reproductive endocrine-mediated perturbations | |
| PMID:20708649 | IVR | 2 mg/kg/day | 2 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Alters aromatase activity in gonads | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30147652 | IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects leydig cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects leydig cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects leydig cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| PMID:30223319 | IVR | 1 mg/kg | 1 mg/kg | Affects leydig cells function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg | 2 mg/kg | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects sertoli cells function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects sertoli cells function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects sertoli cells function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects leydig cells function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects leydig cells function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31927052 | IVTH | 0.0000000125 - 0.0000001 M | 0.0000000125 - 0.0000001 M | Increased cortisone levels | Neurological endocrine-mediated perturbations |
| PMID:32504733 | IVTH | 0.0000001 M | 0.0000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 - 2 mg/kg/day | 0.5 - 2 mg/kg/day | Affects cholesterol transport | Metabolic endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 2 mg/kg/day | 1 - 2 mg/kg/day | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 - 2 mg/kg/day | 0.5 - 2 mg/kg/day | Affects cholesterol biosynthesis | Metabolic endocrine-mediated perturbations | |
| PMID:37156404 | IVR | 1 mg/kg/day | 1 mg/kg/day | Increased Aspartate aminotransferase (AST) level | Hepatic endocrine-mediated perturbations |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 1 - 2 mg/kg/day | 1 - 2 mg/kg/day | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 - 2 mg/kg/day | 0.5 - 2 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 - 2 mg/kg/day | 0.5 - 2 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Reduced glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Increased Aspartate aminotransferase (AST) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 0.5 - 2 mg/kg/day | 0.5 - 2 mg/kg/day | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:6661580 | IVR | 20 mg/kg/day | 20 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| PMID:9100293 | IVR | 3.1 mg/kg | - | No significant effects observed | - |
| IVR | 4.7 mg/kg | 4.7 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 4.7 mg/kg | 4.7 mg/kg | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| IVR | 6.3 mg/kg | 6.3 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 6.3 mg/kg | 6.3 mg/kg | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| IVR | 12.5 mg/kg | 12.5 mg/kg | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 12.5 mg/kg | 12.5 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Pregnancy complications | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.